Another EU Filing Targets Burgeoning NMOSD Market
Executive Summary
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
You may also be interested in...
Lengthy EU Regulatory Review Ends Well For Roche’s NMOSD Therapy
The European Medicines Agency has finally recommended pan-EU marketing approval for Roche’s Enspryng.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Migraine & Hepatitis B Prevention Products Among New EU Filings
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.